NCT07253103

Brief Summary

The goal of this clinical trial is to learn if physical exercise improves quality of life, frailty and mental health in patients with multiple myeloma. It will also learn about the safety and adherence of the program. The main questions it aims to answer are: Does physical exercise improves quality of life in patients with multiple myeloma? Does physical exercise improves frailty and mental health in patients with multiple myeloma? Researchers will compare supervised physical exercise and home-based unsupervised physical exercise. Participants will: Participate in one of the exercise programs, supervised or home-based, for 12 weeks. They will be completely evaluated before and after the intervention.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
4mo left

Started Feb 2026

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress45%
Feb 2026Sep 2026

First Submitted

Initial submission to the registry

November 16, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

November 28, 2025

Completed
2 months until next milestone

Study Start

First participant enrolled

February 1, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2026

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Expected
Last Updated

November 28, 2025

Status Verified

November 1, 2025

Enrollment Period

3 months

First QC Date

November 16, 2025

Last Update Submit

November 24, 2025

Conditions

Keywords

CancerExerciseMĂșltiple MyelomaPhysiotherapyProtocolResistance

Outcome Measures

Primary Outcomes (1)

  • Health related quality of life

    The primary outcome measure will be health related quality of life. Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ). Specifically, the EORTC QLQ-C30 will be used, which is widely used to assess quality of life in cancer patients \[X\]. This instrument consists of 30 items, 24 of which are grouped into five functional domains: physical, role, emotional, cognitive, and social. It also includes three symptom scales-fatigue, pain, and nausea/vomiting-and an overall health status scale. Six other items assess additional symptoms such as dyspnoea, loss of appetite, insomnia, constipation, diarrhoea, and financial difficulties. Responses are recorded on a four-point scale ('none,' 'a little,' 'quite a bit,' 'a lot'), except for the general health and quality of life scales, which use a seven-point format. On the functional and overall health scales, higher scores indicate better health, while on the

    12 weeks

Secondary Outcomes (8)

  • Frailty

    12 weeks

  • Anxiety and depression

    12 weeks

  • Fatigue

    12 weeks

  • Sleep quality

    12 weeks

  • Physical activity

    12 weeks

  • +3 more secondary outcomes

Study Arms (2)

Intervention group

EXPERIMENTAL

Supervised physical exercise program

Other: Supervised physical exerciseOther: Home-based physical exercise program

Control group

EXPERIMENTAL

Home-based physical exercise program

Other: Home-based physical exercise program

Interventions

Participants will follow a supervised physical exercise program for 12 weeks.

Intervention group

Participants will follow a home-based physical exercise program for 12 weeks.

Control groupIntervention group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Confirmed diagnosis of MM undergoing active treatment.
  • No regular physical activity during the previous eight weeks.
  • Functional status (ECOG) 0-1.
  • Signature of informed consent.

You may not qualify if:

  • Presence of medical contraindications for physical exercise, such as severe musculoskeletal disorders, severe cardiovascular disease, bone metastases, or other conditions that the medical team considers inappropriate.
  • Inability to complete the initial assessment tests or difficulty performing basic exercises.
  • Any other circumstance that, in the opinion of the investigators, may interfere with the objectives or conduct of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Fairman CM, Zourdos MC, Helms ER, Focht BC. A Scientific Rationale to Improve Resistance Training Prescription in Exercise Oncology. Sports Med. 2017 Aug;47(8):1457-1465. doi: 10.1007/s40279-017-0673-7.

    PMID: 28074412BACKGROUND
  • Kirkham AA, Eves ND, Shave RE, Bland KA, Bovard J, Gelmon KA, Virani SA, McKenzie DC, Stohr EJ, Waburton DER, Campbell KL. The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT. Breast Cancer Res Treat. 2018 Feb;167(3):719-729. doi: 10.1007/s10549-017-4554-4. Epub 2017 Nov 6.

    PMID: 29110150BACKGROUND

MeSH Terms

Conditions

Multiple MyelomaMotor ActivityNeoplasms

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System DiseasesBehavior

Central Study Contacts

Carlos Martin Sanchez, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Given the study design, it will not be possible to blind participants or assessors to the intervention. However, in order to preserve the objectivity of the results, the statistical analysis will be performed by an independent statistician who is not involved in the study and is unaware of the allocation of participants to the different groups.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

November 16, 2025

First Posted

November 28, 2025

Study Start

February 1, 2026

Primary Completion

May 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

November 28, 2025

Record last verified: 2025-11